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The c-myc oncogene stimulates ribosomal biogenesis and protein synthesis to promote
cellular growth. However, the pathway by which cells sense and restore dysfunctional mRNA
translation and how this is linked to cell proliferation and growth is not known. We here show
that mRNA translation stress in cis triggered by the gly-ala repeat sequence of Epstein–Barr
virus (EBV)-encoded EBNA1, results in PI3Kδ-dependent induction of E2F1 mRNA translation
with the consequent activation of c-Myc and cell proliferation. Treatment with a speciﬁc
PI3Kδ inhibitor Idelalisib (CAL-101) suppresses E2F1 and c-Myc levels and causes cell death
in EBNA1-induced B cell lymphomas. Suppression of PI3Kδ prevents E2F1 activation also in
non-EBV-infected cells. These data illustrate an mRNA translation stress–response pathway
for E2F1 activation that is exploited by EBV to promote cell growth and proliferation, offering
new strategies to treat EBV-carrying cancers.
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Cellular growth and proliferation is coordinated by E2Ftranscription factors via multiple downstream targetgenes, including cyclins and c-myc1,2. The E2Fs are
retained in an inactive state by binding to the retinoblastoma
protein (pRb), p130 and p107 pocket proteins3. The phosphor-
ylation of pRb by cell cycle kinase activity releases E2Fs and
triggers the exit from G0 into G1 and S-phase and cellular pro-
liferation4–6. The pRb–E2F interaction is the target of oncogenic
viruses such as the human papilloma virus (HPV), Simian virus
40 (SV40) and adenovirus that via E7, Large T and E1A,
respectively, compete for E2F binding to pRb7–9. To date, ten E2F
transcription factors have been described, with E2F1–6 binding
the same DNA consensus motif. Whereas E2F1–3 are gene acti-
vators, E2F4–6 are considered suppressors1.
Downstream of the c-myc oncogene are numerous target genes
regulating most aspects of cellular biology, illustrating the com-
plex homoeostasis required to coordinate cellular growth and
division10. Stimulation of ribosomal biogenesis by c-Myc is an
important aspect of cellular growth11 but the pathways that sense
ribosomal activity and how this feeds back and is integrated with
growth and proliferative signalling pathways are poorly
understood.
The endemic form of Burkitt’s lymphoma is characterised by
translocation of c-myc to the immunoglobulin locus and by
expression of the Epstein–Barr virus (EBV)-encoded EBNA1,
which is the only viral antigen expressed in this cancer12,13. But
the role of c-Myc in controlling host cell proliferation during
normal EBV infection is unknown. Two independent transgenic
EBNA1 mouse models show inverse correlation between the
levels of EBNA1 expression and lymphoma incidence14,15. The
phenotype discrepancy between high and low EBNA1-expressing
animals has not been explained. EBV is also tightly associated
with other human cancers, most notably nasopharyngeal carci-
noma and Hodgkin’s lymphoma, but despite knowing the link
between EBV and human cancers for over half a century, the
oncogenic activities of EBV are barely understood16.
EBNA1 carries a repeat sequence of glycines and alanines
(GAr), which suppresses EBNA1 mRNA translation in cis in
order to minimise the production of EBNA1-derived antigenic
peptides for the major histocompatibility (MHC) class I path-
way17,18. The translation inhibitory capacity of the GAr in cis
makes it a unique tool for studying the cellular response to
dysfunctional mRNA translation19.
The PI3Kδ belongs, together with PI3Kα and PI3Kβ, to the
class IA of the PI3K family that use phosphatidylinositol (4,5)
bisphosphate (PI(4,5)P2) as a substrate to generate the lipid sec-
ond messenger PI(3,4,5)P3 following tyrosine kinase receptor
activation and the recruitment of the p85-type regulatory sub-
units in complex with the p110 catalytic subunits20. The PI (3, 4,
5) P3 activates AKT-dependent and AKT-independent down-
stream pathways that control a broad range of cell responses
including proliferation, metabolism and survival. The p110α and
p110β subunits are expressed ubiquitously while p110δ is pre-
dominantly expressed in leucocytes but is also detected in tumour
cells of solid origin21–23. The activation of B cell and cytokine
receptors increase (PI(3,4,5)P3) levels in a p110δ-dependent
fashion and p110δ plays important roles in the inﬂammatory and
allergenic response and mutated p110δ is found in patients suf-
fering from primary immunodeﬁciency24. The compartmentali-
sation and homoeostasis of the TLR4 is regulated by p110δ
independently of mTOR25. The immune regulatory capacity of
p110δ also includes T cell-mediated immune tolerance, giving it a
potential broad role in cancer development26. Drugs such as
Idelalisib (CAL-101) that speciﬁcally inhibit p110δ are used to
treat chronic lymphocytic leukaemia, follicular B cell Hodgkin
lymphoma and relapsed small lymphocytic lymphoma27.
We have exploited the unique capacity of the EBNA1 to sup-
press its own mRNA translation in cis to show how mRNA
translation stress is integrated with growth stimulatory pathways.
We show that EBV, like the simian, adeno and human papilloma
viruses also targets E2F1 but by using a unique mechanism that
does not involve the pRb but requires the activation of the PI3Kδ
and the induction of E2F1 synthesis. The data help explain the
oncogenic activity of EBNA1 and suggests that in addition to
suppressing the production of antigenic peptides, EBNA1-
mediated mRNA translation also promotes cell growth and
proliferation.
Results
The GAr stimulates c-Myc and cell proliferation. The
glycine–alanine (GAr) repeat of the EBV-encoded EBNA1 dis-
rupts mRNA translation in cis and offers a unique tool to study
the cell biological effects of disrupted translation of individual
mRNAs that cannot be achieved using chemical compounds17–19.
When the GAr was expressed in H1299 human carcinoma cell
lines, a signiﬁcant increase (~35%) in colony formation was
observed when compared to plasmid control (EV) (Fig. 1a and
Supplementary Fig. 1a). The notion that the expression of the
GAr promotes cell proliferation was supported by ﬂuorescence-
activated cell sorting (FACS) analysis showing an average 30%
increase of cells in S-phase expressing the GAr under normal
growth conditions. The GAr-dependent increase in proliferation
was further enhanced (from 11 to 19%) in cells that had reached
conﬂuence and the most notable increase was observed under
conditions of low serum when the expression of the GAr resulted
in a near threefold increase from an average 3.6 to 11.1% (Fig. 1b
and Supplementary Fig. 1b). The GAr has a more prominent
effect on translation inhibition when fused to the 5′, as compared
to the 3′, end of open reading frames (ORFs) (Fig. 1c, lower
panels). Expression of three different constructs carrying the GAr
in the N terminus (the chicken ovalbumin (Ova), p53 or GFP)
induced an increase of cells in S-phase ranging from 18, 27 and
40%, respectively. However, GAr fused to the C terminus had
little effect on cell proliferation, despite the GAr-fusion protein
being expressed at high levels (Fig. 1c, upper graph). Similarly,
when altered GAr sequences were expressed in which the trans-
lation disrupting capacity was compromised by changes in the
repeat sequence28, we observed a direct correlation between cell
proliferation and translation inhibition (Supplementary Fig. 1c).
Thus, the presence of the GAr in the cells per se does not have an
effect on cell proliferation and only when it attenuates translation.
Taken together, these results show a link between GAr-mediated
suppression of mRNA translation in cis and cell proliferation.
The link between EBNA1 and c-Myc is manifested in Burkitt’s
lymphoma by the translocation of c-myc gene to the immuno-
globulin (Ig) locus but the correlation between c-Myc and EBNA1
under normal conditions has remained an enigma. When we
expressed an increasing amount of full-length GAr (0.2–1.0 µg
DNA in transfection) in H1299 cells, we observed a dose-
dependent increase in c-Myc levels (Fig. 1d). We observed a
similar increase in c-Myc following expression of GAr in Saos-2
and A549 cells (Supplementary Fig. 2). The c-myc 5′ UTR
supports cap-independent translation and fusion of this RNA
sequence to the 5′ UTR of GAr-Ova (IRES GAr-Ova) is sufﬁcient
to overcome translation inhibition without altering the coding
sequence, resulting in high levels of GAr-Ova but without the
induction in c-Myc expression (Fig. 1e)19,29. Expression of a GAr
cDNA construct resulted in an approximately sixfold increase in
c-myc mRNA levels at 16 h following transfection that reached a
peak of about tenfold at 36 h. In parallel, the mRNA levels of the
c-Myc target gene CAD started to increase at 24 h and peaked at
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48 h (Fig. 1f, upper and lower graphs). Similarly, when we
expressed EBNA1 WT in H1299 cells, there was a signiﬁcant
induction of c-Myc, whereas an EBNA1 construct lacking the
GAr sequence (EBNA1 ΔGAr) had no effect, conﬁrming the
importance of the GAr in c-Myc induction (Fig. 1g). We also
observed a signiﬁcant increase in mRNA levels of c-Myc Pol II
(Cdk4, Cyclin D1, Rps19 and Rpl38) and Pol I (45S pre-rRNA)
target genes following GAr expression (Fig. 1h). When the c-Myc
inhibitor F4-10058 was added, we observed an ~80% suppression
of cells in S-phase at 16 µM in control cells, whereas the
corresponding suppression in GAr-expressing cells at the same
concentration was about 40% (Supplementary Fig. 3a). However,
the suppression proﬁle of CAD mRNA levels by F4-10058 was
similar in cells expressing the GAr compared to control cells
(Supplementary Fig. 3b). This discrepancy between preventing
cell proliferation and c-Myc target genes indicates that other
GAr-induced factors are promoting cell proliferation. The
treatment with F4-10058 did not prevent the GAr from inducing
c-Myc expression (Supplementary Fig. 3c).
Induction of c-myc mRNA levels by GAr is mediated by E2F1.
In order to identify the GAr-dependent factor activating the c-
myc promoter, a series of constructs that include the P1 and P2 of
the c-myc promoter were fused to a Renilla luciferase reporter
gene. Three constructs spanning from (−2052 to +34), (−462 to
+34) and (−107 to +34), all induced luciferase mRNA levels fol-
lowing expression of the full-length GAr (Fig. 2a). The induction
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Fig. 1 GAr-induced mRNA translation stress stimulates cell proliferation via c-Myc. a Colony forming assay. The number of colonies of H1299 cells
expressing the gly-ala repeat (GAr) of the EBV-encoded EBNA1, or plasmid control (EV), were counted after 15 days in selection medium and plotted. b
The graph shows the percentage of proliferating cells (S-phase) expressing the GAr or EV under indicated growth conditions as determined by FACS
analysis. c Western blots (lower panel) show that fusing the GAr to the N terminus of the open reading frames of chicken ovalbumin (Ova), (GAr-Ova),
p53 (GAr-p53) or GFP (GAr-GFP) suppresses mRNA translation, in contrast to when inserted at the C-terminal end (Ova-GAr or p53-GAr). The graph
(upper panel) shows the relative number of cells in S-phase expressing the indicated constructs. d Western blots show the expression of c-Myc following
expression of the indicated quantities of GAr cDNA in H1299 cells. The numbers below the blots indicate c-Myc levels normalised to actin. e Fusing the 5′
UTR of c-myc that contains IRES to the 5′ of GAr-Ova (IRES GAr-Ova) abrogates translation suppression and averts c-Myc induction. f The upper graph
shows RT-qPCR of c-mycmRNA levels at indicated time points following expression of the GAr. The data show the relative c-myc/GAPDHmRNAs ratio and
the highest value at 36 h is set to 100%. The lower graph shows the relative values of c-Myc-induced CAD mRNA levels relative to GAPDH. The highest
value is set to 100%. g RT-qPCR analysis show the relative c-myc mRNA levels normalised to GAPDH in H1299 cells expressing EV, EBNA1 WT or
EBNA1 ΔGAr. h RT-qPCR analysis of c-myc target genes (Cdk4, cyclin d1, 45S pre-rRNA, Rps19 and Rpl38) in cells expressing EV or GAr. Note the
logarithmic scale. FACS analyses show mean values with s.d. from at least three independent experiments. Actin was used as a loading control. For western
blots, RT-qPCR and colony formation assays representative of three independent experiments were shown with s.d. Statistical signiﬁcance was calculated
using t tests (***p< 0.001, **p< 0.05 and *p< 0.1)
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of the Renilla reporter gene (−107/+34) did not take place when
the translation inhibitory capacity of the GAr was abolished by
placing the c-myc IRES in the 5′ UTR (Fig. 2b). All constructs
include the E2F-binding site and the capacity of the GAr to
activate the shortest c-myc promoter construct (−107 to +34)
were severely hampered when three nucleotides were mutated
(Mut1) in the E2F-binding site and completely abolished when
ﬁve mutations were introduced (Mut2) (Fig. 2c). To further
address the role of E2F in the GAr-mediated induction of c-Myc,
we carried out DNA ChIP assays on the c-myc (−107 to +34)
reporter constructs and we used antibodies against E2F1, E2F2 or
E2F3. Quantitative PCR revealed an over threefold increase in
E2F1 binding to the c-myc promoter following expression of the
GAr and minor binding with E2F2 and E2F3. This was precluded
when we use E2F-binding site mutant (Mut1 and Mut2) con-
structs (Fig. 2d). We also carried out ChIP assays on the endo-
genous c-myc promoter and we conﬁrmed an increase in E2F1
binding following GAr expression (Supplementary Fig. 4a). The
GAr-mediated activation of the c-myc promoter was also
observed in mouse embryo ﬁbroblast (MEF) cells (Supplementary
Fig. 4b). Also, when we silenced E2F1 using siRNA, we observed a
decrease in c-Myc levels both in normal and GAr-expressing cells
(Supplementary Figs. 4c and 4d). Furthermore, expressing
EBNA1 WT, as compared to EBNA1 ΔGAr, resulted in a sig-
niﬁcant increase in E2F1 expression (Fig. 2e and Supplementary
Fig. 4e, f). Next, we tested the GAr effect on other E2F1
transcriptional target genes and could observe an approximately
four- and sevenfold increase in the levels of Cyclin E and Cyclin B
mRNAs (Fig. 2f).
GAr triggers post-transcriptional increase of E2F1 levels. We
next set out to understand how E2F1 is activated by GAr-
mediated translation stress. Quantitative RT-PCR following
expression of GAr resulted in an over sixfold induction of c-myc
mRNA levels, without affecting the levels of E2F1 mRNA, sug-
gesting that activation of E2F1 is post-transcriptional (Fig. 3a).
Viral factors such as HPV E7, adenovirus E1A and SV40 large
T activate E2F by preventing the interaction with the pRb protein.
As the expression levels per se are not important for GAr-
mediated induction of E2F1 it is unlikely that the GAr would
mimic the function of these viral proteins and prevent the
E2F1–pRb interaction. In line with this, we observed that
overexpression of pRb resulted in a complete suppression of
GAr-mediated activation of E2F1, as measured by Cyclin E
mRNA levels. However, whereas 0.2 µg of pRb cDNA was
sufﬁcient to inhibit E2F activity in the control cells, a threefold
excess was required to achieve a similar effect in cells expressing
the GAr (Fig. 3b). The hypothesis that the GAr is not targeting
the pRB–E2F interaction was further supported by the observa-
tion that overexpression of HPV E7 resulted in a strong induction
of E2F activity in control cells but resulted in only a marginal
further increase in E2F activity in cells expressing the GAr-Ova
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(Fig. 3c). During the transition from G0 to G1, pRb becomes
phosphorylated by cyclin-dependent kinase (CDK) activity,
which results in the release of E2F1. When we treated control
cells with the CDK inhibitor roscovitine, we observed reduced
levels of c-Myc but this effect was signiﬁcantly less in cells
expressing the GAr (Fig. 3d). Free active E2F1 has a higher
turnover rate and these three observations are consistent with
higher levels of an active E2F1 in GAr-expressing cells. In support
of this, we observed that an increase in the levels of pRb resulted
in an increase in E2F1 protein levels in cells expressing the GAr-
GFP compared to cells expressing GFP alone (Fig. 3e). A similar
increase in E2F1 levels was observed using the proteasome
inhibitor (MG132) (Fig. 3f). We did not observe E2F1 induction
when GAr was expressed under c-myc IRES control (Supple-
mentary Fig. 4g).
Induction of E2F1 is mediated via its coding sequence. An
increase in E2F1 protein synthesis by the GAr was observed using
35S-metabolic pulse labelling followed by E2F1 immunoprecipi-
tation (Fig. 4a). As the mRNA levels of E2F1 do not change
following expression of the GAr, this is consistent with the GAr
triggering an increase in the rate of E2F1 mRNA translation.
Expression of E2F1 constructs that include the 5′ and the 3′ UTRs
(E2F1 UTR), or the coding sequence alone (CDS), resulted in a
similar GAr-dependent increase in E2F1 expression, indicating
that the increase in the rate of E2F1 mRNA translation is not
mediated by the classic regulation of translation that acts via the
untranslated sequences (Fig. 4b). Polysomal proﬁling followed by
RT-qPCR analysis of E2F1 mRNA showed signiﬁcant enrichment
of E2F1 mRNA in the polysomal fractions in cells expressing the
GAr compared to empty vector (EV), indicative of more ribo-
somes being linked to the E2F1 mRNA and, thus, a higher rate of
protein synthesis (Fig. 4c). Other mRNAs, such as BiP and p21,
did not show an increase in polysome fractions (Supplementary
Fig. 5) indicating that the increase in E2F1 level under GAr
induction is not a result of global translation increase. Further-
more, deletion mutants of the E2F1 CDS truncated from the 5′
showed that the ﬁrst 432 nucleotides of the CDS contain the GAr-
responsive element (Fig. 4d). Interestingly, Δ(+1 to +324) showed
low expression in the absence of GAr and a strong induction,
suggesting that regulation of E2F1 synthesis is mediated via two
RNA domains and might involve the release of a negative acting
factor. In support of this, we observed that the deletions Δ(+1 to
+525) and Δ(+1 to +585) resulted in higher levels of expression
but reduced E2F1 induction (Fig. 4e). Together, these results
point towards mRNA structure motif/s being the target for GAr-
dependent induction of E2F1 mRNA translation.
mRNA translation stress induces E2F1 via PI3Kδ. The induc-
tion of E2F1 synthesis following disruption of mRNA translation
on GAr-carrying polysomes is likely to be relayed by a signalling
pathway. Some of the described signalling pathways known to
affect global cap-dependent mRNA translation act via mTOR and
the phosphorylation of 4E-BP1, or via S6 kinase30. However, 8 h
treatment with the mTOR inhibitor rapamycin, or with AKT-
inhibitors, had no effect on GAr-mediated induction of E2F1
expression (Fig. 5a and Supplementary Fig. 6). This is in line with
data showing that the trans-effect of the GAr on mRNA trans-
lation is mediated via the CDS and not via sequences in the
UTRs. We also tested inhibitors against the MAPK, cell cycle
kinases, DNA-PK, ATM and several other kinases linked to
growth control but with little effect. However, when we tested two
general PI3K inhibitors, wortmannin and LY94002, we observed a
complete inhibition of GAr-mediated induction of E2F1 (Fig. 5a
and Supplementary Fig. 7a). Inhibitors of different PI3Ks catalytic
subunits showed that the PI3Kδ-speciﬁc inhibitor CAL-101, but
not inhibitors of p110α, p110β or p110γ, suppressed GAr-
mediated induction of E2F1 (Fig. 5b and Supplementary Figs. 6
and 7a). Wortmannin efﬁciently prevented phosphorylation of
PI3K downstream targets AKT and the mTOR substrate 4E-BP1
in cells, where PI3K activity had been induced following treat-
ment with 40 ng/ml of PDGF for 30 min in serum-free medium.
However, CAL-101 had less effect on phosphorylation of AKT
and little effect on phosphorylation of 4E-BP1 under these con-
ditions (Fig. 5c). In line with this, there was no GAr-dependent
effect on the phosphorylation of AKT and 4E-BP1, showing the
speciﬁcity of PI3Kδ activation (Fig. 5d and Supplementary Fig. 6).
A role for p110δ in the control of E2F1 expression was further
supported using siRNA against p110δ. Importantly, suppression
of p110δ expression using siRNA also reduced E2F1 levels in
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kinase inhibitor roscovitine. e Western blots showing the levels of E2F1 in cells expressing GFP or GAr-GFP following increasing amounts of pRb. f The
levels of E2F1 expression following treatment with the proteasome inhibitor (MG132). The data presented in a, b and c show the means from three
independent experiments with s.d. The mRNA levels were normalised against GAPDH and the reference value 100 was set for non-transfected cells.
Statistical signiﬁcance was calculated using t tests (***p< 0.001). Western blots represent n≥ 3 and actin was used as a loading control
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non-GAr-treated cells, indicating that the p110δ-dependent E2F1
regulatory pathway is not unique to EBNA1 activity (Fig. 5e and
Supplementary Fig. 7b). GAr-dependent induction of E2F1 is
further stimulated following treatment with general PI3K sti-
mulant (LPS [1 µg/ml] and MgSO4 [20 mM])31 and was com-
pletely suppressed by the addition of CAL-101 (10 µM). This was
also observed in EBV-infected lymphoblastoid B95-8 cells (Fig. 5f
and Supplementary Figs. 6 and 7c). In line with this, E2F1 levels
were reduced signiﬁcantly upon CAL-101 treatment in H1299
cells expressing EBNA1 WT as compared to EBNA1 ΔGAr
(Supplementary Fig. 7d). There are no apparent changes in the
expression levels and localisation pattern of p110δ in cells
expressing the GAr (Fig. 5d and Supplementary Fig. 8).
PI3Kδ mediates EBNA1 oncogenic activity. Several oncogenic
viruses target the E2F1 pathway but this has not yet been shown
for the EBV. Nevertheless, EBNA1 has been implicated in
having an oncogenic activity and a transgenic EBNA1 animal
model in which EBNA1 transgene expression was driven by the
immunoglobulin heavy chain (EµEBNA1) showed an inverse
correlation between EBNA1 expression and lymphoma pheno-
type14. To test if the oncogenic properties of EBNA1 are related
to activation of p110δ, we used an EµEBNA1 mouse-derived
primary lymphoma cell line. Treatment with CAL-101 in culture
showed a dose-dependent increase in cell death starting at 10
µM (Fig. 6a). Three further independent primary tumours from
different mice of the same transgenic line (EµEBNA1.26)14
showed a CAL-101-mediated cell death starting at 2 days of
treatment (10 µM) (Fig. 6b). EBNA1 transgenic cells showed
increased expression of both c-Myc and E2F1 compared to the
non-transgenic wild-type (WT) lymphocytes (Fig. 6c and Sup-
plementary Figs. 9a and 9b) and we observed loss of both E2F1
and c-Myc expression after 1 day of treatment at 10 µM
(Figs. 6c, d and Supplementary Fig. 9c). To test if CAL-101-
mediated cell death is linked to EBNA1 expression, we com-
pared a cell line derived from an LMP1 and EBNA1 bi-
transgenic lymphoma (3959.48) to an LMP1-only cell line
(39.415)14,32. The LMP1 and EBNA1 bi-transgenic cells are
EBNA1-dependent and treatment with CAL-101 at 50 µM
resulted in death, while the EBNA1-independent (39.415) cell
line showed no increase in cell death (Fig. 6e). We also treated
the EBV-positive Burkitt’s lymphoma (BL) Raji cells and EBV-
negative BL41 cells with CAL-101 and we observed a suppres-
sion of E2F1 in Raji but with less effect in BL41 (Fig. 6f). Raji
cells carry the BL characteristic c-myc gene Ig translocation,
whereas B95.8 is an EBV-transformed lymphoblastoid cell line
and do not have the c-myc translocation. Only in the B95.8, and
not in the Raji cells, did we observe a CAL-101-dependent
suppression of c-Myc expression (Fig. 6g). These results support
the hypothesis that EBNA1 exerts an oncogenic activity via
GAr-dependent activation of E2F1 and the consequent induc-
tion of c-Myc.
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Discussion
By disrupting mRNA translation in cis using the unique prop-
erties of the gly-ala repeat of the EBNA1 we can show that cells
respond to mRNA translation stress by a PI3Kδ-dependent
activation of E2F1 synthesis and the induction of c-Myc. We have
also shown how this pathway accounts for EBNA1 oncogenic
activity in a transgenic animal model. It is well described how
upregulation of c-Myc induces ribosomal biogenesis to promote
protein synthesis and these results illustrate a feedback pathway
from the ribosome to c-Myc, whereby the cell senses the status of
the mRNA translation and triggers a pathway aimed at restoring
dysfunctional protein synthesis. We propose that this pathway is
exploited by the EBV to promote cell growth (Fig. 7).
The pool of induced E2F1 is active and not bound to pRb. In
line with this, we found that overexpression of the papilloma E7
protein had only a marginal effect on E2F1 activity in GAr-
expressing cells. The induction of E2F1 by PI3Kδ is at the level of
increased mRNA translation and is unusual in the sense that it is
mediated via the coding sequence of the E2F1 mRNA, and not via
the more commonly used 3′ and 5′ UTRs. This indicates an
mRNA-speciﬁc regulation that helps to explain how broad inhi-
bitors of the PI3K catalytic subunits, such as wortmannin and
LY294002, can efﬁciently block GAr-dependent induction of
E2F1, while inhibitors of AKT or mTOR that control general cap-
dependent translation have little, or no effect. We are currently
trying to identify the PI3Kδ substrate that controls E2F1 synthesis
and based on the deletion series of the E2F1 coding sequence it is
likely this factor is an RNA structure-binding protein. This shows
conceptual similarity to the induction of p53 synthesis following
DNA damage, which is also mediated by a stress-responsive RNA
structure in the coding sequence of the p53 mRNA33. The role of
PI3Kδ in the mRNA translation stress response was unexpected
as this family of kinases is normally associated with extracellular
growth stimulatory factors and activation by tyrosine kinase or G-
protein-coupled receptors. However, a hint that PI3Kδmight play
a role in the EBV life cycle is suggested by the observation that
patients who develop the gain-of-function condition, activated
PI3Kδ syndrome (APDS), typically suffer from chronic EBV (and
other herpesviruses) viraemia34. It is interesting that suppression
of PI3Kδ inhibits E2F1 expression also in cells that do not express
the GAr, which implies a broader role of this pathway in con-
trolling E2F1 expression. It is, thus, likely that cellular messages
also trigger this pathway and that a high rate of protein synthesis
can help explain PI3Kδ activity also in solid cancers. PI3Kδ
inhibitors have been effective in treating chronic lymphocytic
leukaemia (CLL) and indolent Hodgkin’s lymphoma and these
results help to better understand the underlying molecular
mechanisms. Hodgkin’s lymphomas are associated with EBV in
~40% of cases and it will be interesting to see if there is a cor-
relation between EBV-carrying cancers and Idelalisib efﬁcacy. In
support of this, we observed that bi-transgenic lymphoma cells
depending on EBNA1 are sensitive to CAL-101 treatment.
Nasopharyngeal carcinomas that carry the EBV and express
EBNA1 in 100% of the cases is another type of cancer in which
this pathway might be of therapeutic interest.
Activation of E2F1 is a common strategy by oncogenic viruses
to promote cell proliferation but this has previously not been
demonstrated for EBV. Papilloma, adenovirus and simian SV40
viruses have developed strategies to activate E2Fs by expressing
factors that disrupt the interaction with pocket proteins. The
EBNA1 has evolved a different route that instead exploits a cel-
lular pathway that aims to restore ribosomal activity via activa-
tion of E2F1 under conditions of dysfunctional ribosomal activity.
The same inhibition of mRNA translation in cis by the GAr forms
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part of the viral strategy to evade the MHC class I-restricted
antigen presentation pathway. Hence, targeting mRNA transla-
tion allows the virus to hit two birds with one stone: evade the
immune system and at the same time support the proliferation of
infected cells. Despite being the only EBV antigen expressed in all
BL and also consistently expressed in all other EBV-associated
tumours such as nasopharyngeal carcinomas, the oncogenic
activity of EBNA1 has remained an enigma. An inverse correla-
tion between EBNA1 levels and the penetrance of B cell lym-
phomas was reported14,15. Additionally, c-Myc was found to be a
noted player in these EBNA1 tumours, showing upregulated
expression (Supplementary Fig. 9a). Importantly, we can now
show that E2F1 and c-Myc expression in primary lymphomas
derived from the lymphoma-prone EµEBNA1 mice are indeed
inhibited following CAL-101 treatment. It is, thus, likely that the
reported inverse correlation between the expression levels of
EBNA1 and the lymphoma phenotype in the EµEBNA1 animals
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can be explained by the induction of E2F1 by EBNA1-mediated
mRNA translation stress. In line with this, c-Myc levels decrease
after CAL-101 treatment in EBV-infected lymphoblastoid cells,
but not in Burkitt’s lymphoma (BL) cells where the transcription
of c-myc is deregulated through translocation to an immu-
noglobulin locus.
Methods
Cell culture and treatments. Unless mentioned otherwise, experiments were
performed mostly using H1299 cells (non-small-cell lung carcinoma human cell
line) [NCI-H1299 (ATCC® CRL5803™)]. Other cell lines used were Raji (type III
latency Burkitt’s lymphoma), B95.8 lymphoblastoid cell line. All cell lines were
cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 2
mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (Invitrogen) and 5
µg/ml Plasmocin prophylactic (Invivogen). Cell lines were routinely checked for
mycoplasma contamination using PlasmoTest kit (Invivogen). Two mouse B cell
lymphoma cell lines were used: 39.415 established from an LMP1 driven transgenic
mouse tumour and 3959.48 established from an LMP1 and EBNA1-positive bi-
transgenic mouse tumour32. Primary tumour cells from lymphomas derived from
the EµEBNA1 transgenic mouse line 2614, or in vivo passages of these tumours, or
wild-type (non-transgenic) splenocytes were explanted, red blood cells lysed and
cultured directly, or frozen for subsequent culture. Starvation experiment allowed
the cells to grow for 72 h with complete medium supplemented with 0.1% foetal
bovine serum. H1299 stable cell lines were generated through transient transfection
of neomycin gene-containing pcDNA3 vectors. After 2 to 3 weeks, geneticin
resistant populations were selected and gene stability was veriﬁed for at least ten
passages.
Lymphoma cells were cultured in RPMI (with L-glutamine, 10% FBS) with 50
µM 2ME in primary cultures. CAL-101 was dissolved in DMSO and supplemented
in cultures from 10 to 100 µM daily. Live cell counts and cell viability were
determined by trypan blue exclusion and counted using the Countess Automated
Cell Counter (Thermo Fisher Scientiﬁc).
Plasmid DNAs and siRNAs. The full-length GAr cDNA expression vector was
isolated from the Epstein–Barr virus (strain B95-8)-encoded EBNA1 and cloned
next to ovalbumin cDNA or p53 cDNA. The generated pcDNA3 constructs, GAr,
Ova, GAr-Ova, Ova-GAr, p53, GAr-p53, p53-GAr, c-myc IRES-Ova and c-myc
IRES GAr-Ova, were described in earlier reports17,19. The GAr cDNA was cloned
in the peGFP-N1 vector generating a GAr-GFP fusion protein with GAr at the
NH2 terminal (GAr-GFP). E2F1 coding sequence was ampliﬁed from the cmv-
E2F1 (provided by Dr O. Bishof, Inst. Pasteur, Paris) and cloned in to pcDNA3
vector. E2F1 CDS deletion constructs were created using pcDNA3-E2F1 (CDS)
ampliﬁed with corresponding primers (listed in Supplementary Table. 1) and
cloned into pcDNA3 vector. The pRB construct was provided by Dr O. Bischof and
CMV-HPV16-E7 is an expression vector for high-risk HPV16-E7 oncoprotein that
was provided by Dr K. Münger (Brigham & Women’s Hospital, MA). The pGL2-
Basic luciferase reporter vector containing the human c-Myc promoter (−2052/
+34), (−462/+34) and (−107/+34) were kindly provided by Professor LZ Penn
(Toronto Medical Discovery Tower, ON, Canada).
Using site-directed mutagenesis, sequential deletions of the human c-myc
promoter (−107/+34) were performed to generate two mutated DNA fragments,
designated (−107/+34) Mut1 and (−107/+34) Mut2. For silencing, E2F1 siRNA 1
(2970963, Qiagen), E2F1 siRNA 2(2824210, Qiagen), AllStars scramble siRNA
(SI03650318, Qiagen), p110δ siRNA 1 (2989964, Qiagen), p110δ siRNA 2
(2996913, Qiagen), E2F3 siRNA (2965187, Qiagen) were used. For transfection of
plasmid DNA and siRNA, GeneJuice (EMD Chemicals) and INTERFERin
(Polyplus-transfection) reagents were used according to the manufacturer’s
instructions.
Western blotting. Cells were lysed in BC200 lysis buffer (200 mM NaCl, 0.2% NP-
40, 10% (v/v) glycerol, 1.0 mM dithiothreitol (DTT), 1.0 mM EDTA, and 25 mM
Tris-HCl, pH 7.8) containing 1% (v/v) eukaryotic protease inhibitor cocktail
(Calbiochem). Equal protein amounts were loaded and resolved in 4–12% Bis–Tris
Plus Gels (Thermo Fisher), transferred on BioTrace NT pure nitrocellulose blotting
membrane (PALL Corporation) and blocked with 5% non-fat dry milk in Tris-
buffered saline pH 7.6 containing 0.1% Tween-20. Proteins were then probed with
corresponding antibodies; anti-E2F1 rabbit pAbs [1:1000] (C-20, Santa Cruz), anti-
GA rabbit pAbs raised against the gly-ala sequence of EBNA1 protein [1:500], anti-
p53 rabbit pAbs (CM-1) [1:1000], anti-GFP mouse mAbs [1:1000] (clones 7.1 and
13.1, Roche), anti-chicken egg ovalbumin rabbit pAbs [1:1000] (Sigma-Aldrich),
anti-c-Myc mouse mAbs [1:500] (9E10, Santa Cruz and Y69 Abcam: #32072) and
anti-actin mouse pAbs [1:2000] (AC-15, Sigma-Aldrich), anti-p110δ rabbit pAb
[1:1000] (H219 Santa Cruz), anti-AKT rabbit mAb [1:1000] (2938, Cell Signaling),
anti-P-AKT rabbit mAb [1:500] (9271, Cell Signaling), anti-4E-BP1 rabbit mAb
[1:1000] (9644, Cell Signaling), anti-p-4E-BP1 rabbit mAb [1:1000] (2855, Cell
Signaling). Uncropped blots are available in supplementary information.
Colony formation assays. Twenty-four hours post transfection, 1.105 pcDNA3
(vector control) or pcDNA3-GAr–transfected H1299 cells were trypsinized and
selected in growth medium supplemented with geneticin. Surviving colonies were
allowed to grow for 15 days and stained with 4% (v/v) Giemsa stain. Colonies were
then quantiﬁed using Clono counter programme.
Flow cytometry. Cells expressing indicated constructs were ﬁxed by overnight
incubation in cold 70% ethanol. After 30 min incubation with 100 U/ml RNase A
(Sigma-Aldrich) at 37 °C, propidium iodide (10 µg/ml)–stained cells were analysed
with an LSR ﬂow cytometer and CellQuest software (Becton-Dickinson).
ChIP assays. ChIP assays were performed using a kit according to the manu-
facturer’s instructions (Upstate). The cleared samples were incubated overnight
with the anti-E2F1 (H137) anti-E2F2 (sc-632) or anti-E2F3 (sc-56666) rabbit
polyclonal antibodies. Antibody/protein/DNA complexes were then co-
precipitated with the beads according to the kit recommendations and the DNA
was recovered by phenol/chloroform extraction and ethanol precipitation. The P2
promoter region (−83/+30) of the human c-myc gene was ampliﬁed by qPCR (see
Supplementary Table. 1 for primer sequences).
Quantitative reverse transcription-PCR. Total RNA was extracted with RNeasy
Mini Kit (Qiagen) following the manufacturer’s instructions. cDNA synthesis was
carried out using the Moloney murine leukaemia virus reverse transcriptase and
Oligo(dT) Primer (Invitrogen). RT-qPCR was performed on StepOne real-time
PCR system (Applied Biosystems) using Perfecta SYBR Green FastMix, ROX
(Quanta Biosciences) (See Supplementary Table. 1 for target primer sequences).
Polysome proﬁling. Five–ﬁfty percent wt/vol linear sucrose gradients were freshly
casted on SW41 ultracentrifuge tubes (Beckmann) using the Gradient master
(BioComp instruments) following the manufacturer’s instructions. Forty-eight
hours post transfection, H1299 cells (with 80% conﬂuency) were treated with
cycloheximide 100 µg/ml for 5 min at 37 °C and then washed twice with 1× PBS
(Dulbecco modiﬁed PBS, GIBCO) containing cycloheximide 100 µg/ml. Cells were
then scrapped and lysed with polysome lysis buffer (100 mM KCL, 50 mM HEPES-
KOH, 5 mM MgCl2, 0.1% NP-40, 1 mM DTT, cycloheximide 100 µg/ml, pH 7.4).
Lysates were then loaded on a sucrose gradient and centrifuged at 222228×g for 2 h
at 4 °C in a SW41 rotor. Samples were then fractionated using Foxy R1 fraction
collector (Teledyne ISCO) at 0.5 min intervals35,36. RNA puriﬁcations from frac-
tions were performed using Trizol-LS reagent (Invitrogen) combined with ethanol
precipitation. Reverse transcription for the target mRNAs were carried out using
equal volume of DNA free RNA from fractions and then normalised with actin
levels.
Metabolic pulse label. Twenty-four hours post transfection, cells were cultured for
1 h in Dulbecco’s modiﬁed Eagle’s starvation medium (Sigma-Aldrich) (without
methionine, cysteine and L-glutamine supplemented with 2% dialysed foetal
bovine serum together with 20 µM of proteasome inhibitor MG132. Cells were
metabolically labelled for 1 h with 45 µCi/ml of EasyTag Express 35S-methionine
Protein Labelling Mix (Perkin-Elmer). E2F1 protein was then immunoprecipitated
and the newly synthesised protein were resolved in 4–12% Bis–Tris Plus Gels and
visualised on autoradiograph.
Immunoﬂuorescence staining. Cells were grown in cover slips for 24–48 h (for
growing non-adherent cells, cover slips were treated ﬁrst with 0.01% poly-L-lysine
solution [Sigma]) and ﬁxed with 4% paraformaldehyde (for H1299 cells were ﬁxed
48 h post transfection), permeabilized with 0.4% Triton X-100, 0.05% CHAPS in
PBS. Cells were then blocked using 3% BSA, 0.1% saponine in PBS and incubated
with anti-PI3Kδ mouse mAb [1:200] (sc-136032) for 2 h at RT and with ALEXA-
488 anti-mouse antibody [1:500] for 45 min at RT, stained with DAPI and washed
with PBS. Cover slips were then dried and mounted in slide using DAKO ﬂuor-
escent mounting medium. Cells were then analysed by Zeiss Axiovert inverted
microscope.
Drugs. MG132 (474790-5, Calbiochem), ATMi (118500, Calbiochem), DNA-PK
Inhibitor II (260961, Calbiochem), AKT Inhibitor VIII (124018, Calbiochem),
Rapamycin (553210, Calbiochem), SB203580 (559389, Calbiochem), Wortmannin
(681675, Calbiochem), F4-10058 (F3680, Sigma-Aldrich), Roscovitine (R7772,
Sigma-Aldrich), AS-605240 (S1410, Selleck Chemicals), CAL-101 (S2226, Selleck
Chemicals), A-66 (S2636, Selleck Chemicals), LY294002 (1130, Tocris Bioscience),
LPS LipoPolySaccharide (L2880, Sigma-Aldrich).
Statistical analysis. Statistical signiﬁcance was analysed by comparing data with
reference point using two-tailed t tests, p < 0.05 was considered statistically sig-
niﬁcant (***p < 0.001, **p< 0.05 and *p< 0.1). All statistical assessment was per-
formed using the Microsoft excel programme.
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Data availability. The authors declare that data supporting the ﬁndings of this
study are available within the article and supplementary ﬁle, or available from the
corresponding author on reasonable request.
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